Bioequivalence and Bioavailability Forum 10:47 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Bioanalysis discontinued subject [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2018-08-02 11:14  - Posting: # 19127
Views: 838

Hi Johanne,

first of all, from a data perspective I agree with what Helmut said.

However, I recall a case where the authority interpretation of a withdrawn consent was that if a trial subject withdraws her consent, then it implicitly also implies that she withdraws her permission for the CRO to touch the un-analysed samples she has given up until the time of consent retraction. This is of course a matter of interpretation, but actually it also makes sense to me.
When it comes to rights of trial subjects there is no reason to take any chances. In this regard we need to think about ICH E6 §2.3 - rights, safety and well-being before science. Other clauses are in play, too.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,256 registered users;
online 12 (0 registered, 12 guests [including 11 identified bots]).

[…] our greatest mistake would be to forget that data
is used for serious decisions in the very real world,
and bad information causes suffering and death.    Ben Goldacre

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed